However, TERC rs35073794 was associated with an approximately 3.4-fold decrease in the odds of individuals younger than 44 years developing MS according to the dominant, overdominant, and additive models (OR: 0.295, (95% CI: 0.173–0.503), p < 0.001; OR: 0.295 (95% CI: 0.173–0.503), p < 0.001; OR: 0.295 (95% CI: 0.173–0.503), p < 0.001, respectively) (Table 7). This evidence concerns the gene TERC and myeloid sarcoma.